| Trial ID: | L2636 |
| Source ID: | NCT00306644
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: Change from baseline of the composite intima-media thickness (IMT) in the carotid artery following 52 weeks of treatment., 52 weeks | Secondary: Plaque occurrence & stenosis within the right carotid artery., 52 weeks
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
556
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2002-05
|
| Completion Date: |
2004-11
|
| Results First Posted: |
|
| Last Update Posted: |
2016-09-01
|
| Locations: |
GSK Investigational Site, Malmö, SE-205 02, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00306644
|
